Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
04:53pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
02:53pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Can BioMarin (BMRN) Keep the Earnings Surprise Streak Alive?
04:10pm, Monday, 24'th Oct 2022 Zacks Investment Research
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can BioMarin (BMRN) Keep the Earnings Surprise Streak Alive?
01:33pm, Monday, 24'th Oct 2022
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
11:55am, Monday, 24'th Oct 2022 Zacks Investment Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have ju
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
11:47am, Monday, 24'th Oct 2022 Zacks Investment Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?
09:21am, Monday, 24'th Oct 2022 Zacks Investment Research
Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Universal Health (UHS) to Post Q3 Earnings: What's in Store?
05:17pm, Friday, 21'st Oct 2022 Zacks Investment Research
Universal Health's (UHS) Q3 results are likely to reflect sound segmental performances resulting from a constant pursuit of expansion moves. However, high labor costs might partly offset the results.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
01:11pm, Friday, 21'st Oct 2022 Zacks Investment Research
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
10:32am, Friday, 21'st Oct 2022
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
What's in Store for Novartis (NVS) This Earnings Season?
04:26pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline
02:02pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical CEO on the company's drug pricing strategy
07:45pm, Wednesday, 19'th Oct 2022
Cramer spoke with BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Wednesday.
AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem
04:02pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.
Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly
03:42pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.
